Ocugen, Inc. (OCGN)

Market Cap	527.82M
Revenue (ttm)	5.37M
Net Income (ttm)	-64.02M
Shares Out	312.32M
EPS (ttm)	-0.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,193,408
Open	1.680
Previous Close	1.620
Day's Range	1.631 - 1.840
52-Week Range	0.515 - 1.960
Beta	3.50
Analysts	Strong Buy
Price Target	7.00 (+314.2%)
Earnings Date	Mar 4, 2026

About OCGN

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 95
• Stock Exchange: NASDAQ
• Ticker Symbol: OCGN
• Website: https://www.ocugen.com

Financial Performance

In 2024, Ocugen's revenue was $4.06 million, a decrease of -32.82% compared to the previous year's $6.04 million. Losses were -$54.05 million, -14.31% less than in 2023.

Analyst Summary

According to 2 analysts, the average rating for OCGN stock is "Strong Buy." The 12-month stock price target is $7.0, which is an increase of 314.20% from the latest price.

Price Target

$7.0

(314.20% upside)

Analyst Consensus: Strong Buy